| HOME >> BIOLOGY >> TECHNOLOGY |
MALVERN, Pa., Feb. 6, 2012 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL), a specialty biopharmaceutical company, today announced the appointment of two executive officers, effective immediately. Andrew I. Koven has been named Executive Vice President, Chief Administrative Officer and General Counsel, and Mark A. Glickman has been named Senior Vice President, Sales.
"The leadership appointments we are announcing today advance our efforts to help position Auxilium for sustainable success and the next stage of its evolution," said Adrian Adams, Chief Executive Officer and President of Auxilium. "Collectively, Andrew and Mark's broad expertise and industry experience should significantly enhance our capabilities as we seek to maximize the value of XIAFLEX® and Testim®, deliver on our current pipeline, and capitalize on future growth opportunities to achieve profitability and drive shareholder value."
Mr. Koven has over 26 years of experience practicing law, most of which has been in the pharmaceutical industry. He most recently served as President and Chief Administrative Officer of Neurologix, Inc. Prior to that, Mr. Koven was Executive Vice President and Chief Administrative and Legal Officer at Inspire Pharmaceuticals, Inc., where he oversaw all matters related to legal, quality and compliance, corporate development and licensing and technical operations prior to the strategic acquisition of the company by Merck & Co. From 2007 to 2010 Mr. Koven served as Executive Vice President, General Counsel and Corporate Secretary at Sepracor Inc. before its acquisition by Dainippon Sumitomo Pharma Co in 2009. Before joining Sepracor, Mr. Koven was Executive Vice President, General Counsel and Corporate Secretary at Kos Pharmaceuticals, Inc., where he oversaw the company's legal, compliance and quality assuranc
'/>"/>
| SOURCE Auxilium Pharmaceuticals, Inc. Copyright©2010 PR Newswire. All rights reserved |